This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
4 MedTech Underperformers Poised for a Turnaround in 2021
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull
by Zacks Equity Research
Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Quest Diagnostics (DGX) closed at $123.63, marking a +0.54% move from the previous day.
Why the Earnings Surprise Streak Could Continue for Quest Diagnostics (DGX)
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $121.74 in the latest trading session, marking a +0.51% move from the prior day.
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DGX) Outperforming Other Medical Stocks This Year?
Quest Diagnostics (DGX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.
Quest Diagnostics (DGX) Stock Moves -0.08%: What You Should Know
by Zacks Equity Research
In the latest trading session, Quest Diagnostics (DGX) closed at $118.40, marking a -0.08% move from the previous day.
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
NEOGEN (NEOG) Q2 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
NEOGEN's (NEOG) segmental revenues improve for fiscal second quarter on strong sales of cleaners and disinfectants.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DGX vs. EHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. EHC: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Quest Diagnostics (DGX) closed at $120.85, marking a +0.41% move from the previous day.
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed the most recent trading day at $123.16, moving +0.9% from the previous trading session.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific